Zorevunersen for epilepsies, myoclonic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 12 Mar 2025: Trial registered, NCT06872125
  2. 4 Jun 2025: Trial started, NCT06872125

The trials

NCT04442295: An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

State
Completed
Phase
Phase 1 and Phase 2
People
62 taking part
Started
29 Jun 2020
Primary completion
14 Nov 2023
Arms
Multiple Ascending Doses
Results
None posted
  1. 22 Jun 2020: Trial registered
  2. 29 Jun 2020: Trial started
  3. 14 Nov 2023: Trial completed

NCT04740476: An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

State
Under way
Phase
Phase 2
People
60 planned
Started
20 Jan 2021
Primary completion
31 Mar 2029
Arms
zorevunersen (STK-001) multiple dose levels
Results
None posted
  1. 20 Jan 2021: Trial started
  2. 5 Feb 2021: Trial registered

NCT06872125: A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

State
Under way
Phase
Phase 3
People
170 planned
Started
4 Jun 2025
Primary completion
Mar 2027
Arms
Zorevunersen
Results
None posted
  1. 12 Mar 2025: Trial registered
  2. 4 Jun 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as STK-001 - Multiple Ascending Doses, zorevunersen (STK-001).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.